Dr. Ramaprasad Srinivasan on the Complex Heterogeneity of Kidney Cancer

Srinivasan says enrolling patients in clinical trials that best represents their type of kidney cancer is an appropriate course of action for treatment.

Ramaprasad Srinivasan, MD, PhD, staff clinician in the Urologic Oncology Branch, National Cancer Institute, discusses the complex heterogeneity of kidney cancer. Srinivasan says because there are so many types of kidney cancers, medical professionals must tailor their treatment to each specific patient.

Oncologists should also seek out and consult other practices who have experience in dealing with specific, possibly rare, types of kidney cancers.

Srinivasan says enrolling patients in clinical trials that best represents their type of kidney cancer is an appropriate course of action for treatment.